Comparative analysis of hospitalization risk for incident heart failure in non-Hispanic Black versus non-Hispanic White individuals with type 2 diabetes on empagliflozin (Empa-AA): Insights from real-world data.

Basem M MishrikyDoyle M CummingsYuanyuan FuJacqueline R HalladaySchuyler JonesAndrea D BoanSara JonesShivajirao P PatilJames R PowellAlyssa AdamsWilliam Irish

Published in: Diabetes, obesity & metabolism (2024)

This study showed no significant difference in incident hHF among Black versus White individuals with T2DM following a prescription for empagliflozin.

Keyphrases

heart failure
cardiovascular disease
african american
electronic health record
left ventricular
atrial fibrillation
type diabetes
metabolic syndrome
adipose tissue
skeletal muscle
insulin resistance
weight loss